Apellis set to take on Alexion as FDA clears PNH drug Empaveli

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, May 17, 2021 at 10:52 AM.

  1. #1 cafead, May 17, 2021 at 10:52 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,046
    Likes Received:
    3
    via Apellis Pharma has secured FDA approval for its complement C3 inhibitor Empaveli as a treatment for paroxysmal nocturnal hemoglobinuria (PNH) – with a label that will allow it to challenge Alexion’s established therapies directly.

    article source
     
    Quote

Reply to Thread